Bronchodilator Drugs - Taiwan | Statista Market Forecast

The Bronchodilator Drugs market in Taiwan is anticipated to witness a significant increase in revenue, with projections indicating that it will reach US$109.90m in 2024.
Furthermore, it is expected that the market will experience a steady annual growth rate (CAGR 2024-2029) of 3.56%, resulting in a market volume of US$130.80m by 2029.
In comparison to other countries worldwide, United States is forecasted to generate the highest revenue in this market, estimated to be US$17.34bn in 2024.
Taiwan's demand for bronchodilator drugs is steadily increasing due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator Drugs market in Taiwan has been growing steadily over the years. Taiwan is known for its high-quality healthcare system and the market for Bronchodilator Drugs is no exception.

Customer preferences: Customers in Taiwan are highly conscious of their health and are willing to spend on high-quality healthcare products. Bronchodilator Drugs are widely used by patients suffering from respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market is dominated by a few major players who offer a wide range of products to cater to the diverse needs of patients.

Trends in the market: The market for Bronchodilator Drugs in Taiwan has been growing due to the increasing prevalence of respiratory diseases. The demand for these drugs is expected to increase in the coming years due to the aging population and the rising pollution levels in the country. The market is also witnessing a shift towards combination therapies, which offer better efficacy and convenience to patients.

Local special circumstances: Taiwan has a high prevalence of respiratory diseases, with a significant proportion of the population suffering from asthma and COPD. The country has a well-established healthcare system that provides access to high-quality healthcare services to its citizens. The government has also taken several initiatives to promote the use of generic drugs, which has led to increased affordability and accessibility of Bronchodilator Drugs.

Underlying macroeconomic factors: Taiwan has a strong economy with a high level of industrialization. The country is known for its high-tech industries, which have contributed significantly to its economic growth. The healthcare sector in Taiwan is also well-developed, with a strong focus on research and development. The government has taken several initiatives to promote the growth of the healthcare sector, which has led to increased investment in the development of new drugs and therapies. The country's aging population and the rising pollution levels are also expected to drive the demand for Bronchodilator Drugs in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.